Connect with us

Business

Merck (MRK) earnings Q4 2025

Published

on

Merck (MRK) earnings Q4 2025

Merck on Tuesday reported fourth-quarter earnings and revenue that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. 

But the company posted a modest 2026 outlook that fell short of Wall Street’s expectations as it prepares for a few drugs to lose patent protection later this year and face generic competition. That includes Type 2 diabetes drugs, Januvia and Janumet, and Bridion, a treatment that helps restore muscle function that was blocked during surgery. 

While those medicines aren’t top-selling products like Keytruda, their combined lower sales will likely pressure the company. 

Advertisement

The pharmaceutical giant anticipates its 2026 revenue will come in between $65.5 billion and $67 billion. Analysts expected revenue of $67.6 billion, according to LSEG. 

Merck also expects adjusted earnings to be between $5 and $5.15  per share. That compares with analysts’ estimate of $5.36 per share, according to LSEG.

That range includes a one-time charge of roughly $9 billion, or around $3.65 per share, related to Merck’s acquisition of Cidara, a biotech company that is developing a flu prevention drug. 

The guidance includes “manageable impacts” from the drug pricing deal Merck struck with President Donald Trump in December, as well as his administration’s recent move to pare back the pediatric vaccine schedule in the U.S., according to a company spokesperson.

Advertisement

Under that “most-favored-nation” deal, Merck will voluntarily sell its existing treatments to Medicaid patients at the lowest price offered in other developed nations and guarantee that pricing for new medicine, among other efforts. In exchange, Merck will get a three-year reprieve from tariffs.

Here’s what Merck reported for the fourth quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

  • Earnings per share: $2.09 adjusted vs. $2.01 expected
  • Revenue: $16.4 billion vs. $16.19 billion expected

The company posted net income of $2.96 billion, or $1.19 per share, for the quarter. That compares with net income of $3.74 billion, or $1.48 per share, for the year-earlier period. 

Excluding acquisition and restructuring costs, Merck earned $2.04 per share for the fourth quarter.

Merck raked in $16.4 billion in revenue for the quarter, up 5% from the same period a year earlier.

Advertisement

The results come as Merck slashes $3 billion in costs by the end of 2027, and prepares to offset revenue losses from the upcoming patent expiration of Keytruda in 2028.

Keytruda drives growth amid Gardasil woes

Merck’s pharmaceutical unit, which develops a wide range of drugs, booked $14.84 billion in revenue during the fourth quarter. That’s up 6% from the same period a year earlier.

Sales of Keytruda topped $8.37 billion for the quarter, rising 7% from the same period a year ago. Analysts were expecting revenue of $8.35 billion, according to StreetAccount estimates. 

The increase in Keytruda revenue was driven by higher uptake of the drug for earlier-stage cancers and strong demand for the treatment for metastatic cancers, which spread to other parts of the body, the company said. 

Advertisement

Sales of the more convenient subcutaneous version of Keytruda, which won approval last year, came in at $35 million during the fourth quarter. 

That version of Keytruda is key to Merck’s efforts to offset likely declines in revenue after the original formulation of the drug, which is administered intravenously, goes off patent. 

Meanwhile, Merck’s newer drug Winrevair, which is used to treat a rare, deadly lung condition, recorded $467 million in sales for the quarter, up 133% from the same period a year earlier. 

Analysts had expected the medication to bring in $459 million, according to StreetAccount estimates. 

Advertisement

More CNBC health coverage

The growth of Winrevair, which first entered the market in mid-2024, largely reflects higher uptake in the U.S. and its early launch in some international markets.

Merck continued to see trouble with China sales of Gardasil, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S.

Last February, Merck announced it would halt shipments of Gardasil into China beginning that month. In July, CFO Caroline Litchfield said the company would not resume shipments to China through at least the end of 2025, noting that inventories remain high and demand is still soft.

Gardasil generated sales of $1.03 billion for the quarter, down 34% from the same period a year ago because of lower demand in China. Still, that was in line with what analysts were expecting, according to StreetAccount.

Advertisement

Gardasil’s revenue could face more pressure in 2026. As part of the Centers for Disease Control and Prevention’s changes to the pediatric vaccine schedule, the agency said that children should get one dose of the HPV vaccine instead of the two to three doses recommended on the label.

Merck’s animal health division, which develops vaccines and medicines for dogs, cats and cattle, posted nearly $1.51 billion in sales, up 8% from the same period a year prior. The company said that reflects higher demand across all species. 

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Perdaman progresses 50MW solar farm near Karratha

Published

on

Perdaman progresses 50MW solar farm near Karratha

A Perdaman-backed solar farm looks set to become the foundation tenant of a traditional owner-backed green energy park near Karratha.

Continue Reading

Business

Vacant Perth lot earmarked for office, dwellings in $10m plan

Published

on

Vacant Perth lot earmarked for office, dwellings in $10m plan

A vacant strip of land in Northbridge has been earmarked for an eight-storey office and apartment building.

Skypacts Property Resources has submitted a $10 million plan to build a mixed-use development on 441 William Street.

The 508-square metre lot, currently an unoccupied infill site, sits next to the Perth Mosque and is bound by William Street and Brisbane Place.

According to Skypacts’ application filed with the City of Vincent, the proposed development comprises offices and associated parking from the first to the fourth floor, and nine apartments across the upper levels.

Advertisement

Lateral Planning, on behalf of Skypacts, said the project would be a high-quality development on an underutilised infill site.

“Overall, the proposed development will not detract from the amenity of the area rather, it will significantly enhance it,” the application said. 

“It represents a positive, forward-looking contribution to the locality, by supporting strategic planning goals, and promoting sustainable urban growth.”

RP data shows Skypacts bought the site for about $2.5 million in 2022.

Advertisement

Skypacts Property Resources is owned by Kian Kiong Lee and has a registered address in Nedlands, according to an Australian Securities and Investments Commission document.

About 600 metres away, another vacant Northbridge lot was flagged for development.

A 480-square metre site at 195 Beaufort Street, next to the Ellington Jazz Club, has been vacant for about 20 years.

Advertisement

In May 2024, a development assessment panel approved a $2.4 million proposal to build a four-storey apartment and retail project on the site.

However, the site, with the attached development application approval, was recently listed on the market.

Advertisement
Continue Reading

Business

Ford and Geely in talks for manufacturing, technology partnership, sources say

Published

on

Ford and Geely in talks for manufacturing, technology partnership, sources say


Ford and Geely in talks for manufacturing, technology partnership, sources say

Continue Reading

Business

Analysis: Fiscal realities rein in US’s aggressive Nordic ambitions

Published

on

Analysis: Fiscal realities rein in US’s aggressive Nordic ambitions

ANALYSIS: The negative response of financial markets dissuaded the US president from pursuing his designs on Greenland.

Continue Reading

Business

Pinterest sacks engineers for tracking layoffs

Published

on

Pinterest sacks engineers for tracking layoffs

The social media platform announced last week that it was laying off around 15% of its workforce.

Continue Reading

Business

Brokerages May Start Charging ETF Issuers Distribution Fees, Says J.P. Morgan

Published

on

Brokerages May Start Charging ETF Issuers Distribution Fees, Says J.P. Morgan

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

Continue Reading

Business

Analysis-Ultra-low bond spread unity still out of reach for euro area

Published

on

Analysis-Ultra-low bond spread unity still out of reach for euro area


Analysis-Ultra-low bond spread unity still out of reach for euro area

Continue Reading

Business

Opinion: Net downside in fishing bans

Published

on

Opinion: Net downside in fishing bans

OPINION: The state government may have hooked itself with what looked like an easy political decision.

Continue Reading

Business

Airbnb: Hotel Expansion Is Promising, But The Valuation Leaves Little Room For Error

Published

on

Airbnb: Hotel Expansion Is Promising, But The Valuation Leaves Little Room For Error

Airbnb: Hotel Expansion Is Promising, But The Valuation Leaves Little Room For Error

Continue Reading

Business

Voters concerned about affordability of homeownership, new poll shows

Published

on

Voters concerned about affordability of homeownership, new poll shows

American voters are concerned about being able to afford homeownership amid high housing costs as the electorate prepares to cast ballots in this fall’s midterm elections, a new poll shows.

A poll conducted for the National Association of Realtors by Public Opinion Strategies and Hart Research showed that over half of voters (52%) say that the affordability of housing is a very important voting issue to them.

Advertisement

Sentiment around the housing market remains at a historically low level, as the poll shows that just 17% of voters think now is a good time to buy a home – down from 69% in 2013.

Despite the headwinds affecting housing affordability, homeownership remains a key part of what voters view as the American dream, with 85% calling it an essential part of the American dream, an increase from 79% in 2013 with strong support across political groups.

EFFORTS TO REIN IN WALL STREET LANDLORDS COULD PUSH US HOME PRICES UP, INVESTORS SAY

A California home is up for sale.

Homeownership remains a key part of how voters view the American dream, the NAR poll showed. (Loren Elliott/Bloomberg via Getty Images)

Renters and other non-homeowners expressed concerns about never being able to afford homeownership, with 76% of that group expressing the belief that they will never be able to afford buying a home and 59% saying they want to buy but lack affordable options in their community.

Advertisement

In contrast, just 27% of all voters were concerned about never being able to afford to buy a home and only 21% cited a lack of affordable options in their community as a barrier.

Homeowners in the survey were asked about reasons that are keeping them from moving, with 35% saying their current mortgage rate is low, and they can’t afford a higher rate. 

Additionally, 30% said they would like to buy another home but lack affordable options in their community, while 16% said they would like to sell but can’t afford the taxes from the profit on the sale.

TRUMP SAYS HE’S ‘NOT A HUGE FAN’ OF 401(K) WITHDRAWAL PLAN FOR HOMEBUYERS’ DOWN PAYMENTS

Advertisement
Home with a "for sale" sign

Voters cited a lack of affordable homes as a key barrier to homeownership. (iStock/Getty Images Plus)

Voters across political groups generally said that federal government policies make it harder to buy a home, with majorities of Democrats (56%) and Independents (53%) along with a plurality of Republicans (41%) expressing that sentiment.

The NAR poll also gauged respondents’ views of several congressional proposals aimed at improving housing affordability.

More than four-fifths of all voters, 84%, expressed support for letting prospective home buyers save money tax-free that can be used to buy a home, with over 80% of all political groups.

Over three-fourths of voters, 76%, backed a proposal to provide a one-time option to sell your home without paying taxes on the profit. That idea was most strongly backed by Republicans (87%) and saw some skepticism among Democrats (65%).

Advertisement

HOUSING EXPERT WARNS PRE-PANDEMIC AFFORDABILITY LEVELS MAY NEVER RETURN IN AMERICA

US Capitol Dome

NAR’s poll asked voters about proposals aimed at making housing more affordable. (Mandel Ngan/AFP via Getty Images)

A similar proposal that would increase the amount of profit that sellers can take before having to pay taxes was backed by two-thirds (67%) of voters, with Republicans (78%) and Independents (66%) viewing the idea more favorably than Democrats (58%).

Providing tax incentives requiring building developers to provide affordable rentals for low-income households was backed by 71% of voters, with Democrats more bullish on the idea (90% support) than Republicans (53%).

Incentivizing home rental investors to sell homes to first-time home buyers was backed by 71% of voters, with similar levels of support across political groups. 

Advertisement

GET FOX BUSINESS ON THE GO BY CLICKING HERE

NAR and its polling firm partners then asked voters whether Congress passing those proposals would make it easier to buy or sell a home, and 64% of respondents said that it would, compared to the 9% who think current federal policies make it easier to buy or sell a home.

Continue Reading

Trending

Copyright © 2025